CD4 and non-small cell lung carcinoma: For example, after neoadjuvant chemotherapy, higher levels of epithelial lymphocytes (CD3+CD4+) and epithelial and stromal tumor‐associated macrophages (CD68+) were associated with better outcome in patients with NSCLC.66